Yifei Qinghua Granule is improved by new technologies such as "spray drying and one-step granulation" on the basis of years of clinical research by Professor Park Bingkui, chief researcher of Chinese Academy of Traditional Chinese Medicine. Yifei Qinghua granule is a specific drug for treating lung cancer, which is suitable for all kinds of lung cancer patients in the middle and late stage. Yifei Qinghua Granule, with Guang 'anmen Hospital of Chinese Academy of Traditional Chinese Medicine as the clinical responsible unit, was certified as a quasi-Chinese medicine by 12 provincial cancer hospitals, and obtained the national new drug certificate. Through the clinical observation of 339 cases of lung cancer, it is found that Yifei Qinghua Granule is obviously superior to the control group in the effective rate, tumor focus stability rate, quality of life improvement rate, immune function improvement, 1 year, 2-year, 3-year survival rate and survival time, etc. When combined with radiotherapy and chemotherapy, it can also enhance the curative effect of radiotherapy and chemotherapy and reduce the toxicity of radiotherapy and chemotherapy to digestive tract, hemogram and liver and kidney function. The listing of Yifei Qinghua Granules has attracted the attention of many media at home and abroad, and also attracted patients from all over the world to see a doctor (related news reports). At present, Yifei Qinghua Granule has been successfully listed in Malaysia.

"Clinical and Experimental Research on Yiqi Yangyin Qingre Jiedu Granule in Treating Primary Lung Cancer" won the third prize of scientific and technological progress of traditional Chinese medicine in state administration of traditional chinese medicine 1996 and the second prize of scientific and technological achievements of Chinese Academy of Traditional Chinese Medicine 1990.